Compugen (NASDAQ:CGEN) Issues Earnings Results

Compugen (NASDAQ:CGEN) issued its quarterly earnings data on Monday. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02, FiscalAI reports. Compugen had a net margin of 47.56% and a return on equity of 42.57%. The business had revenue of $3.82 million for the quarter, compared to the consensus estimate of $1.28 million.

Compugen Stock Performance

CGEN stock opened at $1.96 on Monday. Compugen has a fifty-two week low of $1.43 and a fifty-two week high of $3.23. The company has a market capitalization of $185.32 million, a price-to-earnings ratio of 5.16 and a beta of 2.85. The business’s 50 day moving average price is $2.25 and its two-hundred day moving average price is $2.29.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Compugen in a research report on Tuesday, November 3rd. HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price on shares of Compugen in a research note on Monday, October 12th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $5.00.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is an Israeli clinical-stage biotechnology company focused on discovering and developing novel therapeutic and drug targets for cancer and other diseases. The company uses computational biology and artificial intelligence-based approaches to identify previously unrecognized biological mechanisms and translate them into potential medicines.

Compugen’s research has primarily centered on immuno-oncology, with an emphasis on regulating immune responses within the tumor microenvironment.